{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:25:48Z","timestamp":1785551148908,"version":"3.56.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:p>The surgical treatment of osteogenesis imperfecta (OI) is negatively influenced by clinical features such as osteoporosis, limb deformities and bone changes caused by bisphosphonate therapy. Blood loss during femoral nailing surgeries in patients with OI is a serious problem. Platelet anomalies have been associated with an elevation of the serum pyrophosphate originating from the platelets during clotting, even if the causality with the platelet dysfunction has not yet been established. To identify predictive risk factors regarding intraoperative bleeding, a retrospective analysis was conducted on 23 patients aged between 6 and 13 years, affected by OI type III, who were treated to correct femoral deformities or to perform an osteosynthesis for femoral shaft fractures, using the Fassier\u2013Duval telescopic nail. Osteotomies were performed in 14 cases of deformities and in two out of seven cases of fractures. A survey about the bleeding had been obtained by calculating the sum of the blood aspirated and that lost with the gauzes or present on the surgical drapes. To obtain an estimate of the intraoperative blood losses, one must resort to a calculation based on an algorithm that evaluates the ratio between the effective blood loss divided by the total blood volume expected as per age and weight (<jats:italic toggle=\"yes\">\u03b3<\/jats:italic> distribution). The average blood loss was 237.4\u2009ml (0.12\u2009<jats:italic toggle=\"yes\">\u03b3<\/jats:italic>). In seven cases, it was necessary to perform postoperative transfusions, owing to an average blood loss of 502.8\u2009ml (0.27\u2009<jats:italic toggle=\"yes\">\u03b3<\/jats:italic>). Patients aged less than 10 years had a minor blood loss. A greater number of osteotomies was associated with a significant increase of average bleeding (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.046). Patients who were never treated with bisphosphonates showed a significantly greater bleeding rate (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.048). Patients affected by OI type III have a high risk of severe blood loss during surgery, even caused by the platelet disfunction, which characterizes this OI type. In addition to this predisposing factor, there are other risk factors to consider in preoperative surgical planning. In patients who were never treated with bisphosphonates, the bleeding was higher than in the ones treated with bisphosphonates since at least 1 year. The effects of bisphosphonates on bone tissue (such as the medullar canal narrowing and the bone cortex thickening) could reduce the spongious bone amount and the bleeding. Inhibiting the farnesyl pyrophosphate synthase enzyme and reducing the prenylation of many plasma proteins, including the methylene tetrahydrofolate reductase, the bisphosphonates could lead to an alteration of the coagulation cascade. The correlation found with the intake of bisphosphonates, capable of inhibiting the action of the farnesyl pyrophosphate synthase enzyme, thus influencing coagulation, requires further prospective studies with research of the methylene tetrahydrofolate reductase mutation in patients with OI type III undergoing surgical procedures. The number of osteotomies, the patient\u2019s age and the intake of bisphosphonates for at least 1 year seem to be the best predictive factors for blood loss.<\/jats:p>","DOI":"10.1097\/bpb.0000000000000483","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T16:04:56Z","timestamp":1500393896000},"page":"338-343","source":"Crossref","is-referenced-by-count":12,"title":["Intraoperative bleeding in patients with osteogenesis imperfecta type III treated by Fassier\u2013Duval femoral rodding: analysis of risk factors"],"prefix":"10.1097","volume":"27","author":[{"given":"Pietro","family":"Persiani","sequence":"first","affiliation":[{"name":"Department of Anatomic, Histologic, Forensic and Locomotor Apparatus Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Pesce","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrology, Anaesthesiologic and Geriatric Sciences, Azienda Policlinico Umberto I \u2013 Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Martini","sequence":"additional","affiliation":[{"name":"Department of Anatomic, Histologic, Forensic and Locomotor Apparatus Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo M.","family":"Ranaldi","sequence":"additional","affiliation":[{"name":"Department of Anatomic, Histologic, Forensic and Locomotor Apparatus Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"D\u2019Eufemia","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Center for Congenital Osteodystrophies"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zambrano","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Center for Congenital Osteodystrophies"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Celli","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Center for Congenital Osteodystrophies"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Villani","sequence":"additional","affiliation":[{"name":"Department of Anatomic, Histologic, Forensic and Locomotor Apparatus Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jpeds.2015.10.058","article-title":"Body composition in children and adolescents with osteogenesis imperfecta","volume":"169","author":"Palomo","year":"2016","journal-title":"J Pediatr"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J Bone Miner Res"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11914-016-0299-y","article-title":"Advances in the classification and treatment of osteogenesis imperfecta","volume":"14","author":"Thomas","year":"2016","journal-title":"Curr Osteoporos Rep"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00003086-197310000-00040","article-title":"Osteogenesis imperfecta-new perspectives","volume":"96","author":"Solomons","year":"1973","journal-title":"Clin Orthop Relat Res"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1213\/00000539-198906000-00025","article-title":"Osteogenesis imperfecta and hyperthermia","volume":"68","author":"Ryan","year":"1989","journal-title":"Anesth Analg"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood.V39.4.500.500","article-title":"Platelet function and pyrophosphates in osteogenesis imperfecta","volume":"39","author":"Hathaway","year":"1972","journal-title":"Blood"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0022-3476(71)80468-7","article-title":"Increased oxidative metabolism by leukocytes of patients with osteogenesis imperfecta and of their relatives","volume":"78","author":"Humbert","year":"1971","journal-title":"J Pediatr"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/clinchem\/21.1.104","article-title":"Increased inorganic serum pyrophosphate in serum and urine of patients with osteogenesis imperfecta","volume":"21","author":"Armstrong","year":"1975","journal-title":"Clin Chem"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/hae.12020","article-title":"Suspected collagen disorders in the bleeding disorder clinic: a case\u2013control study","volume":"19","author":"Jackson","year":"2013","journal-title":"Haemophilia"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1172\/JCI106589","article-title":"Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone","volume":"50","author":"Russell","year":"1971","journal-title":"J Clin Investig"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jbmr.2486","article-title":"Osteotomy healing in children with osteogenesis imperfecta receiving bisphosphonate treatment","volume":"30","author":"Anam","year":"2015","journal-title":"J Bone Miner Res"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11832-009-0190-9","article-title":"Surgical blood loss during femoral rodding in children with osteogenesis imperfecta","volume":"3","author":"Pichard","year":"2009","journal-title":"J Child Orthop"},{"key":"R16-20230828","first-page":"591","article-title":"Statistics for biomedical sciences","volume":"7","author":"Cesana","year":"2012","journal-title":"Libreria Univ Ed"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0022-3468(96)90827-1","article-title":"Hemodynamic significance of pediatric femur fractures","volume":"31","author":"Lynch","year":"1996","journal-title":"J Pediatr Surg"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"}],"container-title":["Journal of Pediatric Orthopaedics B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01202412-201807000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T19:28:23Z","timestamp":1693250903000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01202412-201807000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bpb.0000000000000483","relation":{},"ISSN":["1060-152X"],"issn-type":[{"value":"1060-152X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}